Exelixis
EXEL
126 hedge funds and large institutions have $1B invested in Exelixis in 2013 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 46 increasing their positions, 32 reducing their positions, and 10 closing their positions.
536% more capital inflows, than outflows
Capital inflows: $107M | Capital outflows: $16.9M
115% more call options, than puts
Call options by funds: $5.42M | Put options by funds: $2.52M
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
70% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 10
44% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 32
9.35% more ownership
Funds ownership: 83.93% → 93.28% (+9.3%)
4% more funds holding
Funds holding: 121 → 126 (+5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OrbiMed
New York
|
+$45.3M |
| 2 |
Jennison Associates
New York
|
+$13.6M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$7.46M |
| 4 |
Visium Asset Management
New York
|
+$6.73M |
| 5 |
HealthCor Management
New York
|
+$6.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$3.95M |
| 2 |
D.E. Shaw & Co
New York
|
-$2.25M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$1.84M |
| 4 |
Platte River Capital
Denver,
Colorado
|
-$1.83M |
| 5 |
Allianz Asset Management
Munich,
Germany
|
-$1.69M |
EXEL Hedge Fund Activity: Q3 2013 in Review
126 of the 3,096 institutional investors tracked by Wall St. Rank reported a position in Exelixis (EXEL) for Q3 2013, worth a combined $1B — up 43% from $702M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new EXEL positions and 10 closed out — a net gain of 7 holders — while 46 added to existing stakes and 32 trimmed.
The largest buyer was OrbiMed, opening a new position worth an estimated $45.3M. The largest seller was T. Rowe Price Associates, cutting an estimated $3.95M.
- 126 institutional investors held Exelixis (EXEL) as of Q3 2013, up from 121 in Q2 2013.
- Funds reported $1B of Exelixis stock for Q3 2013, up 43% quarter-over-quarter.
- 17 funds opened new Exelixis positions in Q3 2013 and 10 closed out, a net change of +7 holders.
- The largest Exelixis buyer in Q3 2013 was OrbiMed, an estimated $45.3M added.
- The largest Exelixis seller in Q3 2013 was T. Rowe Price Associates, an estimated $3.95M sold.
Based on aggregated 13F filings for Q3 2013.